Disease-free survival did not differ significantly between patients who received leucovorin and fluorouracil versus those who received capecitabine in adjusted analyses ( hazard ratio [ HR ] 102 [ 093-111 ; p = 072 ] ) or in unadjusted analyses ( HR 101 [ 95 % CI 092-110 ; p = 086 ] ) .